Bio-Techne Corporation

Equities

TECH

US09073M1045

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-15 pm EDT 5-day change 1st Jan Change
65.52 USD -1.81% Intraday chart for Bio-Techne Corporation -3.96% -15.09%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
RBC Raises Price Target on Bio-Techne to $79 From $75, Keeps Sector Perform Rating MT
Bio-Techne Positioned for Growth Amid Biotech Funding Recovery, UBS Says MT
Bio-Techne Says European Union IVDR Certification Received for Diagnostic Test Tracking Chronic Myeloid Leukemia MT
Transcript : Bio-Techne Corporation Presents at KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum, Mar-19-2024 09:45 AM
Transcript : Bio-Techne Corporation Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 08:30 AM
North American Morning Briefing : Hopes of March -2- DJ
Stephens Adjusts Bio-Techne's Price Target to $87 From $70, Keeps Overweight Rating MT
Deutsche Bank Cuts Bio-Techne Price Target to $85 From $88, Maintains Buy Rating MT
RBC Cuts Price Target on Bio-Techne to $75 From $85, Notes Revenue Growth Turned Negative, Keeps Sector Perform Rating MT
Stifel Nicolaus Downgrades Bio-Techne to Hold from Buy, $65 Price Target MT
Bio-Techne Seeks M&A CI
Transcript : Bio-Techne Corporation, Q2 2024 Earnings Call, Feb 01, 2024
Bio-Techne's Fiscal Q2 Adjusted Earnings Fall, Net Sales Rise MT
Earnings Flash (TECH) BIO-TECHNE CORPORATION Reports Q2 Revenue $272.6M, vs. Street Est of $277.7M MT
Bio-Techne Corporation Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 CI
Bio-Techne Corporation Announces to Pay A Dividend for the Quarter Ended December 31, 2023, Payable February 26, 2024 CI
North American Morning Briefing : Stock Futures -2- DJ
Bio-Techne Corporation Sets New Standard with the Development of A Next-Generation, Protease-Free RNAscope Spatial Multiomics Workflow CI
Transcript : Bio-Techne Corporation Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 09:00 AM
Bio-Techne Corporation Appoints Kim Kelderman as Chief Executive Officer Effective February 1, 2024 CI
Bio-Techne Corporation Appoints Matthew F. Mcmanus as President, Diagnostics and Genomics Segment, Effective January 8, 2024 CI
Bio-Techne Files Drug Master File With US FDA for ExCellerate GMP for Stem Cell Therapy MT
UBS Initiates Coverage on Bio-Techne With Buy Rating, $80 Price Target MT
Transcript : Bio-Techne Corporation Presents at The 6th Annual Evercore ISI HealthCONx Conference, Nov-29-2023 02:10 PM
Transcript : Bio-Techne Corporation Presents at Stephens Annual Investment Conference | NASH 2023, Nov-15-2023 02:00 PM
Chart Bio-Techne Corporation
More charts
Bio-Techne Corporation specializes in the manufacture and marketing of products used in life science research. The group offers reagents and diagnostic tools for researchers, doctors, laboratories, pharmaceutical and biotechnology companies, etc. Net sales break down by family of products as follows: - biological and chemical reagents and analysis tools (74.3%): proteins, antibodies, molecules, culture serums, tools for cell work, tools for the study of proteins, immunoassay tools, etc.; - diagnostic and genomics products (25.7%): reagents and products used in blood analysis, nucleic acid analysis, tissue biopsy, gene analysis, cancer and genetic carrier screening, etc. Net sales are distributed geographically as follows: the United States (56.5%), the United Kingdom (4.4%), Europe/Middle East/Africa (19.4%), China (10%), Asia/Pacific (6.4%), and other (3.3%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
65.52 USD
Average target price
80.68 USD
Spread / Average Target
+23.14%
Consensus
  1. Stock Market
  2. Equities
  3. TECH Stock
  4. News Bio-Techne Corporation
  5. KeyBanc Adjusts Bio-Techne's Price Target to $500 From $600, Keeps Overweight Rating